Kisspeptin

Phase 2Small molecule

MMassachusetts General Hospital

Kisspeptin is one of 87 small molecule programs targeting Hyperprolactinemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperprolactinemiaActive, not recruiting

Hypogonadotropic HypogonadismActive, not recruiting

Insulin SecretionActive, not recruiting

Delayed PubertyActive, not recruiting

AmenorrheaActive, not recruiting

HyperprolactinemiaPhase 2

Active, not recruiting

Hypogonadotropic HypogonadismPhase 2

Active, not recruiting

Insulin SecretionPhase 1

Active, not recruiting

Delayed PubertyPhase 1

Active, not recruiting

AmenorrheaPhase 2

Active, not recruiting

Competition

Competitive Landscape

64 competitors in Insulin Secretion

#DrugCompanyPhaseTrials

Precose

Bayer

Approved

1 2

Cialis

Eli Lilly

Approved

1 3

Octreotide

Johnson & Johnson

Approved

1 4

Glucophage

EMD Serono

Approved

3 5

Decadron

AAspen Global Incorporated

Approved

1 6

Prograf

VVeloxis Pharmaceuticals

Approved

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 8

Cyclosporine a

Novartis

Approved

1 9

Starlix

Novartis

Approved

1 10

Galvus

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Hypogonadotropic Hypogonadism

NCT05896293

Q2 2030

Phase 2Recruiting

Amenorrhea

NCT07224438

Phase 1Recruiting

Reproductive Disorder

NCT07224490

Clinical

Trials by Indication[1]

Reproductive Disorder2 trials

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Completed·—·Phase 1·NCT05633966·13 enrolled

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

Recruiting·SStephanie B. Seminara, MD·Phase 1·NCT07224490·40 enrolled

ISS2 trials

Dampening the Reproductive Axis With Continuous Kisspeptin

Completed·—·Phase 1·NCT05971849·8 enrolled

Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling

Completed·MMassachusetts General Hospital·Phase 1·NCT01438073·96 enrolled

Hypogonadotropic Hypogonadism2 trials

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Completed·—·Phase 2·NCT04648969·18 enrolled

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT05896293·36 enrolled

Delayed puberty1 trial

Kisspeptin in the Evaluation of Delayed Puberty

Completed·MMassachusetts General Hospital·Phase 1·NCT01438034·24 enrolled

Adult1 trial

Kisspeptin Administration in the Adult

Completed·MMassachusetts General Hospital·Phase 1·NCT00914823·256 enrolled

5 more indications

Peptides1 trial

Neuropeptides in Human Reproduction

Completed·MMassachusetts General Hospital·Phase 1·NCT01952782·61 enrolled

Acute Lymphoblastic Leukemia1 trial

Recall by Genotype: Neuropeptide Stimulation

Terminated·—·Phase 1·NCT05901467·16 enrolled

Hyperprolactinemia1 trial

Administration of Kisspeptin in Patients With Hyperprolactinemia

Completed·MMassachusetts General Hospital·Phase 2·NCT02956447·36 enrolled

Insulin Secretion1 trial

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

Completed·MMassachusetts General Hospital·Phase 1·NCT04958109·16 enrolled

Amenorrhea1 trial

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Recruiting·SStephanie B. Seminara, MD·Phase 2·NCT07224438·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Kisspeptin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kisspeptin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kisspeptin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

Kisspeptin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2030

Trials by Indication[1]

Reproductive Disorder2 trials

ISS2 trials

Hypogonadotropic Hypogonadism2 trials

Delayed puberty1 trial

Adult1 trial

Peptides1 trial

Acute Lymphoblastic Leukemia1 trial

Hyperprolactinemia1 trial

Insulin Secretion1 trial

Amenorrhea1 trial

References

Drug Info

Quick Facts

Related News